Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400mg daily standard therapy

Leukemia

Volumn 23, Issue 6, 2009, Pages 1193-1196

  Rea, D ^a,b   Etienne, G ^b,c   Corm, S ^b,d   Cony Makhoul, P ^b,e   Gardembas, M ^b,f   Legros, L ^b,g   Dubruille, V ^b,h   Hayette, S ^b,i   Mahon, F X ^b,c,j   Cayuela, J M ^b,k   Nicolini, F E ^b,l  

^a SAINT LOUIS HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Service d'Hématologie clinique HÔpital Saint Antoine   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h HÔTEL DIEU   (France)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j HÔPITAL PELLEGRIN   (France)

^k Laboratoire Central d'Hematologie   (France)

^l EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ORGANIC CATION TRANSPORTER 1;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; MALE; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 67349262464     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.32     Document Type: Article

References (8)

1. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intentionto- treat analysis. J Clin Oncol 2008; 26: 3358-3363.
2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
3. Druker BJ, Gathmann I, Bolton AE, Larson RA. Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukaemia (CML) in chronic phase. Blood 2003; 10, (abstract 634).
4. Druker BJ, Guilhot F, O'Brien S, Larson RA. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: The 5-year update from the IRIS study. J Clin Oncol 2006; 24, (abstract 18S).
5. Soverini S, Gnani A, Colarossi S, Castagnetti F, Palandri F, Abruzzese E et al. ABL kinase domain mutations are infrequent in early-chronic phase chronic myeloid leukemia patients resistant to imatinib. Haematologica 2008; 93 (s1) (abstract 0107).
6. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499.
7. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258-264.
8. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have a low OCT-1 activity: Higher doses of imatinib therapy may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064-4072.